MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Hospital General Universitario de Elche](/img/noimage_org.png)
Hospital General Universitario de Elche
Elche, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Elche (7)
2023
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial
Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898
2019
-
Clinical impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer treated with first-line chemotherapy plus anti–epidermal growth factor receptor therapy
JCO Precision Oncology, Vol. 3
-
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial
JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573
2018
-
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686
2017
-
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
British Journal of Cancer, Vol. 117, Núm. 12, pp. 1777-1786